Rebirthel Co., Ltd. was founded in October, 2019.
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal
T cells that are regenerated from pluripotent stem cells.
The strategy is based on methods developed by myself, Dr. Hiroshi Kawamoto (Kyoto University).
It has been shown to be effective to transfuse genetically engineered T cells that had originally been collected from patients.
However, such “autologous” settings have faced problems: costly, time-consuming, and dependent on the quality of the T cells themselves (from the patients).
To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting.
Pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells have the potential to produce various types of tissues/organs.
Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells.
Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells.
Certain types of T cells play the role of commander of immune cells, while other types serve as strong warriors.
Therefore, if we can produce different types of T cells - such as killer T cells, helper T cells, or regulatory T cells - covering a wide range of target antigens, we can provide therapeutic T cells targeting any kind of disease related to the immune system (e.g. cancer, infectious diseases, autoimmune diseases, allergies, etc.).
Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.
Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.
Rebirthel took over all projects and intellectual properties related to killer T cells.
･Regcell raised 620,000,000 JPY through a third-party allocation of new shares.
･Regcell raised 20,000,000 JPY through a third-party allocation of new shares.
OP9 cell line and its genetically modified derivatives
Rebirthel has succeeded all rights of the OP9 cells from Dr. Hiroaki Kodama (who originally established the OP9 cell line).
You are required to obtain a license from Rebirthel for commercial use of the OP9 cell line or its derivatives.
Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its recent issue, Rebirthel is introduced. In the article, TCR-iPS cell method and DP method which are our pa...
Professor Hiroshi Kawamoto, an excecutive director of Rebirthel, is recently conducting the collaborative research to develop a new therapy for the novel coronavirus infection with Fujita Health Unive...
This video was taken when our executive director, Hiroshi Kawamoto (Professor, Institute for Frontier Life and Medical Sciences, Kyoto University) visited Fujita Health University at the start of the ...
Rebirthel Co., Ltd. concluded an agreement to collaborate with Fujita Health University to develop a new therapy for novel coronavirus infection and entered into the contract. Killer T cells which are...
Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter OtsukaPharmaceutical) on October 1st 2020. Under this agreement, Rebi...
The world is presently facing the serious situation of the coronavirus pandemic. We all need to work together on a global basis to end this crisis.Unfortunately, the pandemic does not decrease the inc...
We will not use your personal information for any purpose other than contacting customers.